Among the populations medicine has most often failed to reach—low-income, rural, and minority smokers who came not to quit but simply to be screened—a large American trial found that modest cash payments could double the rate of sustained abstinence. The Healthy Lungs trial, enrolling over three thousand adults across five medical centers, quietly challenged a long-held assumption: that readiness to change must precede the offer of help. In a domain where willpower and motivation have long been treated as prerequisites, money proved a more reliable lever than either free medication or digital
Cash rewards double smoking quit rates in underserved populations, JAMA trial finds
Money roughly doubled the quit rate in a population that typically fails to quit.
Mark
So the headline is that cash works. But I'm curious—did it work because people are motivated by money, or because the study design itself was different from earlier trials?
Mimi
Both, probably. But the design point is crucial. Earlier studies enrolled people who'd already decided to quit. This one enrolled anyone referred for lung cancer screening, regardless of whether they wanted to quit. That's a much harder population to move.
Luke
Right, but let's be precise about the numbers. Eight point eight percent quit with incentives. That's still ninety-one percent who didn't. We should be careful not to oversell this.
Mimi
Fair. But compare it to 4.3 percent with standard care. You're doubling the success rate in a population that typically has very low quit rates.
Mark
Why didn't the free medication work? That seems counterintuitive.
Mimi
The researchers don't have a clear answer. They removed the financial barrier, but that alone didn't change behavior. It suggests that access to medication isn't the bottleneck for this population.
Luke
Or it could mean the medications weren't prescribed or used optimally. The paper notes low uptake of varenicline and bupropion, and there was no individualized counseling. So we don't know if free medication would work if it were paired with real support.
Mark
And the app—the future-thinking tool—that seemed to flop.
Mimi
It did. Half the people created initial messages, but engagement dropped off fast. Fewer than a quarter ever updated their cues.
Luke
Which tells us something important: the intervention as designed didn't match how people actually behave. You can't assume that because an idea is theoretically sound, people will use it.
Mark
So what's the takeaway? Just pay people to quit?
Mimi
It's more nuanced. The incentives worked across every subgroup tested—regardless of age, race, income level, or whether someone said they wanted to quit. That consistency is striking.
Luke
But we only know it works for six months, and mostly for twelve. What happens in year two? The paper acknowledges that's unknown. And only one in eight people offered incentives actually collected payments, which raises questions about what's really driving the effect.
O Pulso
- Smoking remains stubbornly entrenched among underserved Americans—Black, Hispanic, rural, and low-income populations—who are least likely to access cessation support and most likely to bear its lethal consequences.
- A trial of 3,220 smokers revealed that free medication, long assumed to be a meaningful barrier to quitting, moved the quit rate only marginally from 4.3% to 5.1%—a near-invisible gain that challenges conventional public health logic.
- Cash incentives of up to $600, tied to biochemically verified abstinence milestones, nearly doubled sustained quit rates to 8.8%, even among participants who had not expressed a desire to quit before enrolling.
- A mobile app designed to help smokers envision a smoke-free future added no measurable benefit—and may have slightly diluted the effect of financial rewards, raising questions about the limits of digital behavioral nudges.
- Most participants who were offered money never collected any payment, yet the incentive still shifted outcomes at the population level—suggesting that the structure of possibility, not just its uptake, can reshape behavior.
- Long-term durability beyond twelve months remains uncharted, leaving open the question of whether financial incentives plant lasting change or merely delay the return of old habits.
Among the populations medicine has most often failed to reach—low-income, rural, and minority smokers who came not to quit but simply to be screened—a large American trial found that modest cash payments could double the rate of sustained abstinence. The Healthy Lungs trial, enrolling over three thousand adults across five medical centers, quietly challenged a long-held assumption: that readiness to change must precede the offer of help. In a domain where willpower and motivation have long been treated as prerequisites, money proved a more reliable lever than either free medication or digital encouragement.
Nearly ten thousand smokers arrived at lung cancer screening clinics across five American medical centers. Researchers turned to roughly a third of them with an unusual proposition: what if quitting came with a paycheck?
The Healthy Lungs trial enrolled 3,220 adults who represented the populations healthcare has historically struggled to serve—Black and Hispanic patients, rural residents, people living near or below the poverty line. Most were in their early sixties, many smoking more than ten cigarettes a day. They hadn't come because they were ready to quit. Researchers enrolled them anyway, dividing them into four groups: standard clinical advice alone; advice plus free medication; medication plus escalating cash payments of $100, $200, and $300 at verified abstinence milestones; and that same package supplemented by a mobile app encouraging future-oriented thinking.
The results were unambiguous in one direction and surprising in another. Standard care produced a 4.3% sustained quit rate at six months. Free medication barely moved that number. But cash nearly doubled it, to 8.8%. The app, meanwhile, added nothing—and may have marginally diluted the incentive's effect, though not significantly so.
Perhaps the most striking finding was that motivation didn't matter. Participants who said they weren't ready to quit responded to financial incentives just as well as those who were. This directly challenges the design of most prior cessation research, which enrolled only self-selected quitters. Here, money worked across the board.
The trial had its limits. Medication uptake was lower than expected, and there was no individualized counseling. Only about one in eight participants who were offered payments ever collected one, yet the population-level effect held. At twelve months, most six-month quitters were still abstinent—but what happens in year two remains unknown.
What the study establishes is narrower but meaningful: for people the healthcare system has long failed to help, money works. Not universally, not perfectly—but reliably enough to matter in communities where smoking-related disease falls hardest.
Nearly ten thousand smokers showed up for lung cancer screening across five American medical centers. Researchers had a question for about a third of them: what if we paid you to quit?
The Healthy Lungs trial enrolled 3,220 adults who fit a particular profile—people the healthcare system has historically struggled to reach. They were Black or Hispanic, living in rural areas, or earning less than twice the federal poverty line. Most were around 61 years old. More than half smoked more than ten cigarettes a day. They came in for screening because their doctors ordered it, not necessarily because they were ready to change. Some had no formal education beyond high school. The researchers didn't ask if they wanted to quit. They enrolled them anyway.
The trial split participants into four groups. One group got the standard approach: a clinician would ask about smoking, advise quitting, and refer them to resources. A second group got that same advice plus free medication—nicotine patches, gum, lozenges, or prescriptions for varenicline or bupropion, fully covered. A third group received the medications and something more: cash. One hundred dollars if they stayed off cigarettes for two weeks, two hundred at three months, and three hundred at six months, verified by urine tests and other biochemical checks. The fourth group got all of that plus a mobile app that sent text messages encouraging them to imagine their smoke-free future.
Six months later, the numbers told a stark story. Among those who received only standard advice, 4.3 percent had quit and stayed quit. Adding free medication bumped that barely—to 5.1 percent. But adding money changed the equation. Nearly 8.8 percent of those offered financial incentives achieved sustained abstinence. The cash roughly doubled the quit rate. Adding the future-thinking app on top of the incentives actually made things slightly worse, dropping the rate to 7.2 percent, though that difference was not statistically significant.
The finding that free medication alone didn't work was perhaps the most surprising. Researchers had expected that removing the financial barrier to pills and patches would help. It didn't. Among the people offered incentives, only about one in eight actually collected any payment—suggesting that even the prospect of money wasn't enough to move most smokers to action. Those who did engage with the mobile tool were sparse: half created initial messages about why they wanted to quit, but fewer than a quarter ever updated those messages or asked for new ones.
When researchers looked at whether people's stated readiness to quit mattered—whether someone who said they wanted to quit responded differently than someone who didn't—they found no meaningful difference. The financial incentives worked across the board, regardless of motivation. This matters because most earlier smoking cessation studies enrolled only people who had already decided to quit. This trial deliberately included people who hadn't made that choice, and the money still moved the needle.
The abstinence held. At twelve months, most people who had quit at six months were still not smoking. But the researchers were cautious about what they could claim. The trial had limitations. Uptake of the prescription medications was lower than expected. There was no one-on-one counseling, no tailored support for using nicotine replacement therapy. The mobile tool may not have worked as intended. And the question of what happens in year two and beyond remains open—earlier research suggests roughly one in ten people who have quit for a year will relapse each year after that.
What the trial does show is this: among people whom the healthcare system has historically failed to help quit smoking, money works. Not perfectly. Not for everyone. But reliably enough that it doubled the success rate. For a population that bears a disproportionate burden of smoking-related disease and often lacks access to cessation support, that difference could matter significantly.
Citações Notáveis
Among medically underserved adults who smoked cigarettes and were referred for lung cancer screening, adding financial incentives to ask-advise-refer care and free pharmacotherapy was associated with higher sustained tobacco abstinence through 6 months.— Healthy Lungs trial authors, published in JAMA
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine